Overview of the Shanghai International Syphilis Symposium (SISS 2025) Authors: Pingyu Zhou, Justin D. Radolf Published: 2026 INTRODUCTION: FRAMING THE FIELD AND THE SPECIAL ISSUE Syphilis continues to resurge as a major global public health challenge, with increasing incidence across diverse geographic and demographic settings. At the same time, the field is undergoing rapid scientific evolution, with advances spanning genomic epidemiology, diagnostics, therapeutics, and vaccine development. However, these advances have not yet translated into sustained reductions in disease burden, highlighting a persistent gap between scientific innovation and real-world implementation. The Shanghai International Syphilis Symposium (SISS 2025) was convened to address this gap by bringing together experts across clinical medicine, basic science, epidemiology, public health practice, and implementation science (Supplemental Figure 2, http://links.lww.com/OLQ/B384). Rather than organizing parallel disciplinary tracks, the meeting adopted a topic-oriented format designed to promote cross-disciplinary dialogue and integration (Supplemental Figure 1, http://links.lww.com/OLQ/B384). In addition, an important objective of SISS 2025 was to foster the next generation of syphilis researchers by inviting and actively engaging early-career investigators and newcomers to the field. By integrating participants at different career stages into the scientific discussions, the symposium sought to promote mentorship, encourage new perspectives, and contribute to the development of a more inclusive and sustainable global research community. This emphasis on capacity building and community formation was viewed as essential for advancement of the field. This overview synthesizes the key scientific themes, areas of convergence, and emerging priorities identified during the symposium and serves as an integrative introduction to the accompanying articles in the SISS special issue. EVOLVING GLOBAL AND GENOMIC EPIDEMIOLOGY AND POPULATION-LEVEL CHALLENGES Presentations on global epidemiology highlighted the increasingly complex and heterogeneous nature of the syphilis epidemic (see Peters et al.1). While many high-income countries are experiencing marked increases in incidence—particularly among men who have sex with men—syphilis remains endemic among heterosexuals in many low- and middle-income countries, where structural barriers to care persist. Across regions, congenital syphilis continues to represent a critical and preventable public health failure. Discussions emphasized the need for improved maternal screening, earlier diagnosis, optimized treatment strategies, and stronger integration of antenatal services. A consistent theme was the need to tailor control strategies to local epidemiologic contexts while informed by global data. In this regard, advances in genomic epidemiology are beginning to transform understanding of Treponema pallidum transmission dynamics (see Peters et al.1). Rapid expansion of genomic sequencing efforts over the past decade has enabled the identification of major lineages and sublineages, revealing both global dissemination patterns and localized transmission clusters. Notably, genomic data have demonstrated a predominance of SS14-like lineages in many regions, alongside evidence of population bottlenecks followed by recent expansion. Beyond lineage tracking, genomic approaches provide important insights into pathogen biology and evolution. The relatively stable genome of T. pallidum, characterized by limited horizontal gene transfer and slow core genome evolution, contrasts with the remarkable diversity generated in loci such as tprK, which facilitates immune evasion through gene conversion. This duality has important implications for both transmission dynamics and vaccine development. Genomic tools are also increasingly being integrated into surveillance systems, enabling detection of antimicrobial resistance markers—such as widespread macrolide resistance—and supporting higher resolution epidemiologic investigations (see Peters et al.1). At the same time, important challenges remain, including limited availability of clinical specimens with sufficient bacterial load for sequencing and the underrepresentation of data from low- and middle-income countries. Collectively, these observations underscore both the transformative potential of genomic epidemiology and the need for more comprehensive and equitable surveillance infrastructures, as well as strengthened research capacity in high-burden regions. FROM POLICY TO PRACTICE: ALIGNING SCIENCE, GUIDELINES, AND IMPLEMENTATION Discussions on policy and strategic priorities highlighted the growing recognition that scientific advances alone are insufficient to reverse current epidemiologic trends. Global strategies, including those led by international organizations, have identified key priorities for syphilis control, but implementation remains uneven. A recurring theme was the disconnect between evidence generation and program delivery (see Peters et al.1; Miranda et al.2). While guidelines continue to evolve, their translation into practice is often constrained by health system limitations, funding gaps, and competing public health priorities. Participants emphasized the need for closer alignment between research, policy development, and implementation, as well as sustained political commitment and global coordination. A key theme emerging from this session was the urgent need for more effective coordination among global health agencies (see Peters et al.1; Miranda et al.2). In an era of shifting and potentially reduced funding from traditional sources, participants emphasized that agencies with global reach must take more active leadership roles. This includes working collaboratively to define shared priorities, coordinate strategies, and ensure that investments are aligned to maximize impact. Without such coordination, fragmented efforts will limit progress despite scientific advances. DIAGNOSTICS AS A BOTTLENECK AND OPPORTUNITY Syphilis presents unique diagnostic challenges that are rooted in both biological and technological limitations (See Klausner et al.3). T. pallidum cannot be cultured using conventional laboratory methods, and the clinical manifestations of infection vary widely across stages, often mimicking other diseases. Serologic testing remains the mainstay of diagnosis, but current assays have major limitations, including the inability to reliably distinguish active from past infection and variability in performance across disease stages. Molecular diagnostics, while offering improved specificity, are often limited by specimen availability and sensitivity, particularly in nonlesional disease. Together, these factors create inherent challenges for accurate and timely diagnosis. Diagnostic innovation was a central theme of SISS 2025, encompassing improvements in serologic testing, lesion-based molecular diagnostics, expansion of self-testing for key populations, and the development of tools for neurosyphilis detection (see Klausner et al.3; Foley et al.4). These advances hold great promise for improving early detection and expanding access to testing. Importantly, discussions consistently framed diagnostics not simply as technological innovations, but as critical components of a broader care continuum. Persistent challenges—including limited access in low-resource settings, fragmentation of testing strategies, and barriers to integration into health systems—continue to limit their real-world impact (see Miranda et al.2; Vester et al.5; Kaunda et al.6). Ensuring equitable access to high-quality diagnostics, particularly for early and congenital syphilis, remains a central challenge (see Miranda et al.2; Klausner et al.3; Foley et al.4; Vester et al.5). Addressing this gap will require not only technological innovation but also implementation-focused research and system-level solutions. These inherent biological and technological constraints underscore why improvements in diagnostic tools must be accompanied by advances in implementation strategies to achieve meaningful impact. TREATMENT AND CLINICAL MANAGEMENT: STABILITY AND INNOVATION Benzathine penicillin G remains the cornerstone of syphilis treatment and continues to be highly effective across disease stages. However, longstanding challenges related to drug supply, administration logistics, and access—particularly in low-resource settings—continue to limit its consistent implementation. These constraints highlight a persistent gap between the availability of effective therapy and its real-world delivery (see Fitzpatrick et al.7; Stuart et al.8). At the same time, the therapeutic landscape is evolving (see Fitzpatrick et al.7). Increasing attention has been directed toward alternative and adjunctive strategies, including doxycycline-based approaches. The expanding use of doxycycline for postexposure prophylaxis reflects a broader shift toward prevention-oriented treatment paradigms, although questions remain regarding long-term effectiveness, adherence, and potential unintended consequences. In parallel, emerging clinical data—including studies from China—suggest that doxycycline may have a role in specific contexts such as neurosyphilis, providing new insights that may inform future guideline development.9 In addition, early-phase investigations of alternative agents are ongoing. For example, linezolid has been proposed as a potential candidate for the treatment of neurosyphilis,10 with clinical studies anticipated, reflecting continued efforts to expand the therapeutic pipeline beyond penicillin-based regimens and to address unmet needs in complex clinical scenarios (see Fitzpatrick et al.7). Across these discussions, a key theme was the need to better integrate therapeutic innovation with implementation. Despite the availability of effective and emerging treatment options, barriers related to health system capacity, drug delivery, and patient engagement continue to constrain impact (see Assi et al.11; Kaunda et al.6; Matoga et al.12). Addressing these challenges will require coordinated efforts that bridge clinical research, public health systems, and implementation science to ensure that advances in treatment translate into meaningful improvements in outcomes. VACCINE DEVELOPMENT IN THE CONTEXT OF THE TRANSLATIONAL PIPELINE The symposium highlighted the recent renewed momentum in syphilis vaccine research, reflecting growing recognition of the need for a long-term preventive strategy to complement existing approaches to diagnosis and treatment (see Giacani et al.13). Advances in immunology, antigen discovery, and structural biology are beginning to inform rational vaccine design, while new platform technologies offer opportunities to accelerate development. An initial presentation in the vaccine session recounted the long history of research relating to protective immunity in rabbits and humans along with the large body of evidence from the premolecular era pointing to the importance of functional antibodies against T. pallidum surface antigens as the basis for vaccine development. Subsequent presentations underscored progress in identifying candidate antigens and elucidating mechanisms of protective immunity, as well as ongoing efforts to develop multivalent strategies targeting outer membrane proteins. At the same time, important scientific challenges remain, including defining correlates of protection, overcoming immune evasion by T. pallidum, and translating promising preclinical findings from animal models into viable vaccine candidates for clinical trials. Overall, the progress being made underscored the potential for vaccines to become a critical component of long-term syphilis control strategies. Continued advances will require coordinated efforts across basic science, translational research, and clinical development, as well as shared infrastructure and standardized approaches to evaluation. BASIC SCIENCE AS AN ENABLER OF TRANSLATIONAL PROGRESS Recent advances with in vitro cultivation of T. pallidum represent a breakthrough in syphilis research and are beginning to transform the field (see Hawley et al.14). The ability to maintain and propagate the organism under laboratory conditions has enabled new experimental approaches previously not feasible, opening the door to innovative investigations of pathogenesis, host–pathogen interactions, and antimicrobial susceptibility. Advances in basic and translational science are also beginning to reshape the treatment landscape. The development of in vitro cultivation systems for T. pallidum now makes possible antibiotic susceptibility testing, representing a critical step toward more evidence-based and individualized treatment strategies. Presentations highlighted how these systems can be applied to study bacterial physiology, evaluate candidate therapeutics, and support the identification and validation of vaccine targets, including outer membrane proteins. These developments also provide a foundation for more systematic and reproducible experimental models, which are essential for advancing translational research. More broadly, the symposium underscored the increasingly central role of basic science—including genomic, structural, and molecular approaches—in driving progress across the syphilis research continuum (see Peters et al.1; Klausner et al.3; Giacani et al.13; Hawley et al.14). By enabling mechanistic insights and supporting the development of new tools, these advances are helping to bridge the gap between discovery and application in diagnostics, therapeutics, and vaccine development. IMPLEMENTATION SCIENCE AND COMMUNITY ENGAGEMENT A major theme emerging from SISS was the critical role of implementation science and community engagement in bridging the gap between scientific advances and real-world impact (see Foley et al.4; Matoga et al.12). Despite substantial progress in diagnostics, treatment, and prevention, persistent barriers—including stigma, limited health literacy, and structural inequities—continue to hinder access to testing and care, particularly among key populations. Presentations emphasized the importance of community-centered and participatory approaches, highlighting how cocreation with affected populations can improve trust, increase testing uptake, and enhance the effectiveness of interventions(Assi et al.11; Matoga et al.12). These approaches are increasingly recognized as essential components of successful public health strategies, particularly in settings where traditional healthcare delivery models face limitations. Emerging digital approaches generated considerable excitement. In particular, the use of artificial intelligence–based tools and chatbot platforms was discussed as a novel strategy to reduce stigma, improve sexual health communication, and promote engagement with testing services (see Matoga et al.12). These innovations illustrate how technology may complement community-based strategies to extend reach and enhance impact. At the same time, participants noted that key areas—including social and behavioral sciences, health economics, and implementation research—remain underrepresented in the current research landscape (see Matoga et al.12). Strengthening these domains will be essential to ensure that scientific advances translate into scalable, equitable, and sustainable syphilis control efforts. STRUCTURED WORKING LUNCHES: FROM DISCUSSION TO CONSENSUS Two structured working lunches were integrated into the SISS 2025 program as deliberate mechanisms to move beyond knowledge exchange toward consensus-building and action-oriented priority setting. One session focused on syphilis diagnostics and implementation challenges, using a structured consensus-building approach based on the nominal group technique. Through premeeting surveys and iterative group discussions, participants identified and ranked key gaps and challenges in syphilis prevention and care and collaboratively developed potential solutions. This process highlighted critical challenges related to diagnostic access, implementation barriers, and integration into health systems, and will inform ongoing qualitative analyses and future dissemination efforts. The second session was led by representatives from WHO and the Gates Foundation and focused on defining priority areas for global syphilis treatment research. Discussions also addressed how to better align scientific priorities with funding strategies and implementation needs in high-burden settings. Importantly, these sessions were not conceived as ancillary activities but as key components of the symposium designed to bridge research, implementation, and funding priorities. By creating structured opportunities for dialogue and consensus-building, they illustrate a model for how multidisciplinary engagement can be translated into coordinated research agendas and actionable strategies for global syphilis control. CROSS-CUTTING THEMES AND GAPS A central objective of SISS 2025 was to move beyond discipline-specific discussions and identify cross-cutting themes and critical gaps that shape the current trajectory of syphilis research and control. Several unifying themes emerged. First, there was a clear emphasis on the need for greater integration across traditionally siloed domains, including diagnostics, treatment, and prevention. Rather than viewing these components in isolation, participants highlighted the importance of a continuum-based approach in which advances in one area are closely linked to progress in others. Second, the symposium underscored the increasingly important role of basic science—including genomic, structural, and in vitro studies—in driving translational advances across the research continuum. Genomic epidemiology is emerging as a critical bridge between population-level surveillance and mechanistic understanding, enabling more precise tracking of transmission, characterization of pathogen diversity, and identification of targets relevant to disease surveillance, diagnostics, therapeutics, and vaccine development. Third, implementation science emerged as a central pillar, with broad recognition that scientific innovation alone is insufficient without effective strategies to ensure uptake, scalability, and sustainability in real-world settings. At the same time, the symposium highlighted several important gaps that continue to limit progress. Notably, there was relatively limited representation of health economics, social and behavioral sciences, and other disciplines essential for understanding how interventions are adopted and sustained. In addition, participants emphasized the need to strengthen research capacity and scientific leadership in high-burden countries, where the impact of syphilis is greatest but resources for research and innovation remain constrained. Persistent data gaps in low- and middle-income countries further hinder effective surveillance, program design, and evaluation. Together, these observations suggest that future progress in syphilis control will depend not only on continued scientific advances, but also on a more balanced and integrated research agenda that incorporates implementation, social science, and capacity-building efforts alongside biomedical innovation. LOOKING TO THE FUTURE: IMPLICATIONS FOR RESEARCH, PRACTICE, AND POLICY The discussions at SISS 2025 highlight several important implications for the readership of Sexually Transmitted Diseases, spanning research, clinical practice, and public health. For researchers, there is a clear need to expand beyond biomedical innovation to include implementation science, social and behavioral research, and health economics. Future studies should prioritize real-world effectiveness, scalability, and context-specific adaptation, particularly in high-burden settings. Strengthening research capacity and leadership in low- and middle-income countries will be essential to ensure that scientific advances are aligned with local needs. For clinicians, emerging developments in diagnostics and treatment—including expanded use of molecular testing, self-testing approaches, and evolving therapeutic strategies such as doxycycline-based regimens—underscore the importance of staying current with rapidly changing evidence (see Klausner et al.3; Foley et al.4; Fitzpatrick et al.7; Stuart et al.8; Assi et al.11). At the same time, clinicians play a critical role in addressing gaps in care, particularly in early detection and prevention of congenital syphilis (see Miranda et al.2; Kaunda et al.6). For public health practitioners and program leaders, the findings emphasize the need to strengthen integrated approaches that link screening, diagnosis, treatment, and follow-up within cohesive systems of care. Expanding access to diagnostics, improving linkage to care, and addressing structural barriers—including stigma and inequities affecting key populations—remain central priorities. In addition, closer alignment between research, policy, and funding strategies will be necessary to maximize the impact of interventions. Taken together, these priorities highlight the need for a coordinated and multidisciplinary approach to syphilis control, in which advances in science are closely coupled with effective implementation to achieve measurable public health impact. Importantly, SISS 2025 was conceived not only as a forum for scientific exchange, but also as a platform for building a more connected and sustainable global syphilis research community. This includes fostering the next generation of investigators and strengthening partnerships across regions and disciplines. Participants expressed a shared commitment to maintaining the momentum generated by the symposium, including the intention to establish SISS as a recurring international meeting and to develop ongoing collaborative platforms that support coordinated research and implementation efforts. These efforts will prompt a shift toward a multidisciplinary and action-oriented approach to syphilis control—one that is essential to achieving meaningful and sustained public health impact. Supplementary Material